--- title: "Radiopharm Theranostics (RAD) news: offering" url: "https://aibio.space/companies/radiopharm-theranostics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "RAD offering news: Radiopharm Theranostics sets $9,300,000 ATM limit, prices $4,050,001.36 ADS sale. Radiopharm Theranostics Limited (ASX: RAD), Australia." --- RAD Radiopharm Theranostics Limited ASX · Australia # Radiopharm Theranostics (RAD) news RAD offering news Financings · 2026-07-23 ## [Radiopharm Theranostics sets $9,300,000 ATM limit, prices $4,050,001.36 ADS sale](https://aibio.space/news/radiopharm-theranostics-sets-9-300-000-atm-limit-prices-4-050-001-36/) Radiopharm amended its at-the-market program to $9,300,000 on July 23, 2026. The next day it announced a $4.1 million registered direct offering at $3.16 per ADS, below the $4.29 last sale price on July 21. ## Latest Radiopharm Theranostics news 1. 2025-12-16 Financings [Radiopharm Theranostics files $50,000,000 ADS shelf, sets $18,900,000 sales program](https://aibio.space/news/radiopharm-theranostics-files-50-000-000-ads-shelf-sets-18-900-000/) Radiopharm Theranostics filed a $50,000,000 shelf registration on December 16, 2025 and a sales agreement with Leerink Partners the same day. A prospectus supplement filed December 23 set up to $18,900,000 of at-the-market sales. ## Radiopharm Theranostics at a glance - **Ticker**: RAD - **Listing**: ASX - **Country**: Australia - **Cash, Jun 30, 2025**: $29.1 million ### Related companies - [Clarity Pharmaceuticals](https://aibio.space/companies/clarity-pharmaceuticals/) ASX: CU6 - [Propanc Biopharma](https://aibio.space/companies/propanc-biopharma/) NASDAQ: PPCB - [Immutep](https://aibio.space/companies/immutep/) ASX: IMM - [Curvebeam AI](https://aibio.space/companies/curvebeam-ai/) ASX: CVB - [Botanix Pharmaceuticals](https://aibio.space/companies/botanix-pharmaceuticals/) ASX: BOT - [Percheron Therapeutics](https://aibio.space/companies/percheron-therapeutics/) ASX: PER - [Calmer Co International](https://aibio.space/companies/calmer-international/) ASX: CCO - [Identifai Genetics](https://aibio.space/companies/identifai-genetics/) ASX: ID1 ### Also on ASX - [Curvebeam AI](https://aibio.space/companies/curvebeam-ai/) CVB - [LTR Pharma](https://aibio.space/companies/ltr-pharma/) LTP - [Invex Therapeutics](https://aibio.space/companies/invex-therapeutics/) IXC - [Tissue Repair](https://aibio.space/companies/tissue-repair/) TRP - [Argenica Therapeutics](https://aibio.space/companies/argenica-therapeutics/) AGN - [Firebrick Pharma](https://aibio.space/companies/firebrick-pharma/) FRE ## What Radiopharm Theranostics does Radiopharm Theranostics Limited describes itself as a research and development company that aims to develop and commercialize platforms of radiopharmaceutical products for therapeutic and diagnostic applications in precision oncology. It says its technologies span peptides, small molecules and antibodies attached to medical quality radioisotopes, and it focuses on radiosensitive tumor types with high mortality rates. Its pipeline builds on licensed platform technologies, including exclusive rights from NanoMab Technologies to anti-HER-2, anti-TROP-2, anti-PD-L1 and anti-PTK7 technology, from TRIMT GmbH to the Ga-Trivehexin technology, and a license from Cancer Research Technology for the F-FPIA imaging agent. Through Pharma15, acquired in March 2023, it is developing next-generation therapeutic radiopharmaceuticals for prostate cancer that seek to overcome resistance to PSMA-targeting therapies. Lantheus is a shareholder and a development partner under a strategic development services contract to advance radiopharmaceuticals in Australia. AtomVie performs development and manufacturing services for 177Lu-BetaBart, a 177Lutetium-conjugated B7-H3 targeting radioantibody. Radiopharm Ventures, a joint venture with MD Anderson, is developing several clinical assets that are in the pre-clinical stage. | Product or program | What it is | Stage | |---|---|---| | 177Lu-BetaBart | Radioantibody targeting B7-H3, conjugated to 177Lutetium | | | NanoMab antibody technologies | Exclusive rights to anti-HER-2, anti-TROP-2, anti-PD-L1 and anti-PTK7 technology | | | Ga-Trivehexin | Technology under exclusive license from TRIMT GmbH | | | F-FPIA imaging agent | Imaging agent under license from Cancer Research Technology | | Summarised from the company's [20-F filed Sep 30, 2026](https://www.sec.gov/Archives/edgar/data/1949257/000121390026105181/ea0306842-20f_radiopharm.htm). ## Radiopharm Theranostics annual financials | Line | FY ended Jun 30, 2025 | FY ended Jun 30, 2024 | |---|---|---| | Revenue | [$3.6 million](https://www.sec.gov/Archives/edgar/data/1949257/000121390025088699/) | | | Research and development | [$27.5 million](https://www.sec.gov/Archives/edgar/data/1949257/000121390025088699/) | [$23.1 million](https://www.sec.gov/Archives/edgar/data/1949257/000121390025088699/) | | Net income (loss) | [-$38.3 million](https://www.sec.gov/Archives/edgar/data/1949257/000121390025088699/) | [-$47.9 million](https://www.sec.gov/Archives/edgar/data/1949257/000121390025088699/) | | Cash from operations | [-$36.6 million](https://www.sec.gov/Archives/edgar/data/1949257/000121390025088699/) | [-$23.0 million](https://www.sec.gov/Archives/edgar/data/1949257/000121390025088699/) | | Cash and equivalents | [$29.1 million](https://www.sec.gov/Archives/edgar/data/1949257/000121390025088699/) | [$18.6 million](https://www.sec.gov/Archives/edgar/data/1949257/000121390025088699/) | Latest balance sheet, Jun 30, 2025 (20-F): cash and equivalents $29.1 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Radiopharm Theranostics Has Radiopharm Theranostics raised money recently? Our latest story on this, dated Jul 23, 2026: "Radiopharm Theranostics sets $9,300,000 ATM limit, prices $4,050,001.36 ADS sale". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/radiopharm-theranostics-sets-9-300-000-atm-limit-prices-4-050-001-36/). What is the ticker symbol of Radiopharm Theranostics? Radiopharm Theranostics Limited trades under the ticker RAD on ASX. Where is Radiopharm Theranostics listed? Radiopharm Theranostics Limited is listed on ASX. Our directory also records these other listings: NASDAQ:RADX. What is the SEC CIK of Radiopharm Theranostics? The SEC Central Index Key (CIK) for Radiopharm Theranostics Limited is 1949257. Its filings are on SEC EDGAR. How many shares does Radiopharm Theranostics have outstanding? 3,544,216,160 shares as of 2026-06-30, per the cover page of its 20-F filed 2026-09-30. Which country or territory is Radiopharm Theranostics listed under? Our directory records Radiopharm Theranostics Limited under Australia. What does Radiopharm Theranostics do? Our directory classifies Radiopharm Theranostics Limited as: Radiopharmaceutical drug developer. This is a directory classification, not a description of the pipeline. What is the ISIN of Radiopharm Theranostics? The ISIN recorded for Radiopharm Theranostics Limited is AU0000181851. Does aibio.space cover Radiopharm Theranostics? aibio.space lists Radiopharm Theranostics Limited among 2,820 public biotech companies and publishes its news here as stories appear. Where is Radiopharm Theranostics incorporated? SEC records list its state or country of incorporation as C3. What does Radiopharm Theranostics develop? Radiopharm Theranostics Limited describes itself as a research and development company that aims to develop and commercialize platforms of radiopharmaceutical products for therapeutic and diagnostic applications in precision oncology. It says its technologies span peptides, small molecules and antibodies attached to medical quality radioisotopes, and it focuses on radiosensitive tumor types with high mortality rates. What is 177Lu-BetaBart from Radiopharm Theranostics? 177Lu-BetaBart: Radioantibody targeting B7-H3, conjugated to 177Lutetium What is NanoMab antibody technologies from Radiopharm Theranostics? NanoMab antibody technologies: Exclusive rights to anti-HER-2, anti-TROP-2, anti-PD-L1 and anti-PTK7 technology What was Radiopharm Theranostics's revenue last year? $3.6 million for the fiscal year ended Jun 30, 2025, as reported to the SEC. Is Radiopharm Theranostics profitable? Radiopharm Theranostics Limited reported a net loss of $38.3 million for the fiscal year ended Jun 30, 2025, and used $36.6 million of cash in operations, per its annual report to the SEC. ## Investor discussion: Radiopharm Theranostics Members talk about Radiopharm Theranostics (RAD). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Radiopharm Theranostics, newest first. Each line links the filing it comes from. 1. 2026-09-14 Financings Set up an at-the-market program to sell shares over time. SEC Form F-3. [Source](https://www.sec.gov/Archives/edgar/data/1949257/000121390026099432/ea0304774-f3_radio.htm) 2. 2026-07-23 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1949257/000121390026080653/ea0298996-424b5_radiopharm.htm) 3. 2025-12-16 Financings Set up an at-the-market program to sell shares over time. SEC Form F-3. [Source](https://www.sec.gov/Archives/edgar/data/1949257/000121390025122349/ea0269469-f3_radiopharm.htm) 4. 2025-10-20 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1949257/000121390025100126/ea026177901ex99-1_radiopharm.htm) 5. 2025-04-29 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1949257/000121390025036386/ea023988701ex99-1_radiopharm.htm) 6. 2025-01-10 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1949257/000121390025002340/ea022733601ex99-1_radio.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open ASX:RAD on TradingView](https://www.tradingview.com/symbols/ASX-RAD/). ## SEC filings and registration - **SEC name**: Radiopharm Theranostics Ltd - **CIK**: 1949257 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: RADX (Nasdaq), RDPTF (OTC) - **State or country of incorporation**: C3 - **Fiscal year ends**: June 30 - **Filer category**: Non-accelerated filer
Emerging growth company - **Business address**: LEVEL 3, 62 LYGON STREET, CARLTON VIC, 3053 - **Phone**: 61 3 9824 5254 - **Shares outstanding**: 3,544,216,160 as of 2026-06-30 (20-F filed 2026-09-30) ### Recent filings (8-K and 6-K are the company's own announcements) - [6-K](https://www.sec.gov/Archives/edgar/data/1949257/000121390026110813/ea0309123-6k_radiopharm.htm) filed 2026-10-20 - [6-K](https://www.sec.gov/Archives/edgar/data/1949257/000121390026106652/ea0307670-6k_radiopharm.htm) filed 2026-10-05 - [6-K](https://www.sec.gov/Archives/edgar/data/1949257/000121390026105456/ea0307317-6k_radiopharm.htm) filed 2026-10-01 - [20-F](https://www.sec.gov/Archives/edgar/data/1949257/000121390026105181/ea0306842-20f_radiopharm.htm) filed 2026-09-30 - [6-K](https://www.sec.gov/Archives/edgar/data/1949257/000121390026104850/ea0307187-6k_radiopharm.htm) filed 2026-09-30 - [6-K](https://www.sec.gov/Archives/edgar/data/1949257/000121390026101968/ea0306179-6k_radiopharm.htm) filed 2026-09-22 - [6-K](https://www.sec.gov/Archives/edgar/data/1949257/000121390026099435/ea0305391-6k_radiopharm.htm) filed 2026-09-14 - [6-K](https://www.sec.gov/Archives/edgar/data/1949257/000121390026098976/ea0305226-6k_radiopharm.htm) filed 2026-09-11 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001949257), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Radiopharm Theranostics Limited is a public biotech or pharmaceutical company listed on ASX under the ticker RAD, recorded under Australia. The directory classifies it as Radiopharmaceutical drug developer. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Radiopharm Theranostics Limited - **Ticker**: RAD - **Listing**: ASX - **Country or territory**: Australia - **Business scope**: Radiopharmaceutical drug developer - **ISIN**: AU0000181851 - **Other listed symbols**: NASDAQ:RADX - **Last quote in directory**: 2026-10-22 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/ASX-RAD/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/radiopharm-theranostics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Radiopharm Theranostics (RAD) news: offering", 2026-10-31, https://aibio.space/companies/radiopharm-theranostics/